Stockreport

Revolution Medicines outlines multiple Phase III trial launches and commercial buildout amid increased R&D investment [Seeking Alpha]

Revolution Medicines, Inc.  (RVMD) 
PDF CEO Mark Goldsmith opened the call highlighting the company's ongoing commitment to “revolutionizing treatment for patients with RAS-addicted cancers through the discov [Read more]